Ukr.Biochem.J. 2026; Volume 98, Issue 2, Mar-Apr, pp. 51-60

Endoplasmic reticulum stress differentially alters the effect of hypoxia on PSAT1 and CYCLIN D1 gene expressions in normal astrocytes and glioblastoma cells

Y. M. Viletska*, M. Y. Sliusar, A. I. Abramchuk, O. V. Halkin,
O. O. Ratushna, O. Y. Luzina, O. H. Minchenko

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
*e-mail: yulya.viletska@ukr.net

Received: 19 September 2025; Revised: 13 October 2025;
Accepted: 03 April 2026; Available on-line: April 2026

Endoplasmic reticulum (ER) stress and hypoxia interaction in the progression of glioblastomas and other malignant tumors has not yet been sufficiently studied. Both PSAT1, as the ER stress-responsive phosphoserine aminotransferase, and сyclin D1 are shown to participate in tumor progression and chemoresistance. Therefore, this study aimed to elucidate the effect of endoplasmic reticulum stress on PSAT1 and CCND1 (сyclin D1) genes expression in normal human astrocytes of NHA/TS line, and U87MG glioblastoma cells. Hypoxia was created with the HIF1A prolyl hydroxylase inhibitor dimethyloxalylglycine. Tunicamycin and thapsigargin were used for ER stress induction. PSAT1 and cyclin D1 expression were examined by quantitative real-time RT-PCR. It has been established that hypoxia and tunicamycin had a similar suppressive effect on PSAT1 and CCND1 expression in normal astrocytes, but increased both genes expression in glioblastoma cells. Thapsigargin enhanced PSAT1 expression in both cell lines, but suppressed CCND1 expression in normal astrocytes without any effect on its expression in glioblastoma cells. Hypoxia modified the effect of tunicamycin and thapsigargin when these ER stress inducers were combined with hypoxia, but in different ways in normal and glioblastoma cells. These results indicate that hypoxia and ER stress relationship in the control of the studied genes expression differs in normal and tumor cells.

Keywords: , , , , , ,


References:

  1. Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B, Luís A, McCarthy N, Montibeller L, More S, Papaioannou A, Püschel F, Sassano ML, Skoko J, Agostinis P, de Belleroche J, Eriksson LA, Fulda S, Gorman AM, Healy S, Kozlov A, Muñoz-Pinedo C, Rehm M, Chevet E, Samali A. Endoplasmic reticulum stress signalling – from basic mechanisms to clinical applications. FEBS J. 2019;286(2):241-278. PubMed, PubMedCentral, CrossRef
  2. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8(9):705-713. PubMed, CrossRef
  3. Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21(8):421-438. PubMed, PubMedCentral, CrossRef
  4. Knaup KX, Monti J, Hackenbeck T, Jobst-Schwan T, Klanke B, Schietke RE, Wacker I, Behrens J, Amann K, Eckardt KU, Warnecke C, Wiesener MS. Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro. Mol Carcinog. 2014;53(12):970-978. PubMed, CrossRef
  5. Doultsinos D, Avril T, Lhomond S, Dejeans N, Guédat P, Chevet E. Control of the Unfolded Protein Response in Health and Disease. SLAS Discov. 2017;22(7):787-800. PubMed, CrossRef
  6. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314. PubMed, CrossRef
  7. Batie M, Rocha S. Gene transcription and chromatin regulation in hypoxia. Biochem Soc Trans. 2020;48(3):1121-1128. PubMed, PubMedCentral, CrossRef
  8. Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. Eur Urol. 2016;69(4):646-657. PubMed, PubMedCentral, CrossRef
  9. Pelizzari-Raymundo D, Maltret V, Nivet M, Pineau R, Papaioannou A, Zhou X, Caradec F, Martin S, Le Gallo M, Avril T, Chevet E, Lafont E. IRE1 RNase controls CD95-mediated cell death. EMBO Rep. 2024;25(4):1792-1813. PubMed, PubMedCentral, CrossRef
  10. Acosta-Alvear D, Zhou Y, Blais A, Tsikitis M, Lents NH, Arias C, Lennon CJ, Kluger Y, Dynlacht BD. XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol Cell. 2007;27(1):53-66. PubMed, CrossRef
  11. Minchenko OH, Khita OO, Krasnytska DA, Viletska YM, Rudnytska OV, Hnatiuk OS, Minchenko DO. Inhibition of ERN1 affects the expression of TGIF1 and other homeobox gene expressions in U87MG glioblastoma cells. Arch Biochem Biophys. 2024;758:110073. PubMed, CrossRef
  12. Minchenko OH, Sliusar MY, Khikhlo YP, Halkin OV, Viletska YM, Khita OO, Minchenko DO. Knockdown of ERN1 disturbs the expression of phosphoserine aminotransferase 1 and related genes in glioblastoma cells. Arch Biochem Biophys. 2024;759:110104. PubMed, CrossRef
  13. Maurel M, Chevet E, Tavernier J, Gerlo S. Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem Sci. 2014;39(5):245-254. PubMed, CrossRef
  14. Hollien J, Lin JH, Li H, Stevens N, Walter P, Weissman JS. Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol. 2009;186(3):323-331. PubMed, PubMedCentral, CrossRef
  15. Almanza A, Mnich K, Blomme A, Robinson CM, Rodriguez-Blanco G, Kierszniowska S, McGrath EP, Le Gallo M, Pilalis E, Swinnen JV, Chatziioannou A, Chevet E, Gorman AM, Samali A. Regulated IRE1α-dependent decay (RIDD)-mediated reprograming of lipid metabolism in cancer. Nat Commun. 2022;13(1):2493. PubMed, PubMedCentral, CrossRef
  16. Auf G, Jabouille A, Delugin M, Guérit S, Pineau R, North S, Platonova N, Maitre M, Favereaux A, Vajkoczy P, Seno M, Bikfalvi A, Minchenko D, Minchenko O, Moenner M. High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor. BMC Cancer. 2013;13:597. PubMed, PubMedCentral, CrossRef
  17. Jiang W, Zhang M, Gao C, Yan C, Gao R, He Z, Wei X, Xiong J, Ruan Z, Yang Q, Li J, Li Q, Zhong Z, Zhang M, Yuan Q, Hu H, Wang S, Hu MM, Cai C, Wu GS, Jiang C, Zhang YL, Zhang CS, Zhang J. A mitochondrial EglN1-AMPKα axis drives breast cancer progression by enhancing metabolic adaptation to hypoxic stress. EMBO J. 2023;42(20):e113743. PubMed, PubMedCentral, CrossRef
  18. Sebestyén A, Kopper L, Dankó T, Tímár J. Hypoxia Signaling in Cancer: From Basics to Clinical Practice. Pathol Oncol Res. 2021;27:1609802. PubMed, PubMedCentral, CrossRef
  19. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8(12):967-975. PubMed, PubMedCentral, CrossRef
  20. Sun RC, Denko NC. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 2014;19(2):285-292. PubMed, PubMedCentral, CrossRef
  21. Fels DR, Koumenis C. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther. 2006;5(7):723-728. PubMed, CrossRef
  22. Bao MH, Wong CC. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells. 2021;10(7):1715. PubMed, PubMedCentral, CrossRef
  23. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem. 2002;277(8):6183-6187. PubMed, PubMedCentral, CrossRef
  24. Denko NC. Hypoxic regulation of metabolism offers new opportunities for anticancer therapy. Expert Rev Anticancer Ther. 2014;14(9):979-981. PubMed, PubMedCentral, CrossRef
  25. Chesney J, Clark J, Klarer AC, Imbert-Fernandez Y, Lane AN, Telang S. Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. Oncotarget. 2014;5(16):6670-6686. PubMed, PubMedCentral, CrossRef
  26. Minchenko A, Caro J. Regulation of endothelin-1 gene expression in human microvascular endothelial cells by hypoxia and cobalt: role of hypoxia responsive element. Mol Cell Biochem. 2000;208(1-2):53-62. PubMed, CrossRef
  27. Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H. Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation. FEBS Lett. 2004;576(1-2):14-20. PubMed, CrossRef
  28. Benej M, Papandreou I, Denko NC. Hypoxic adaptation of mitochondria and its impact on tumor cell function. Semin Cancer Biol. 2024;100:28-38. PubMed, PubMedCentral, CrossRef
  29. Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target. Int J Mol Sci. 2021;22(11):5703. PubMed, PubMedCentral, CrossRef
  30. Taneja N, Chauhan A, Kulshreshtha R, Singh S. HIF-1 mediated metabolic reprogramming in cancer: Mechanisms and therapeutic implications. Life Sci. 2024;352:122890. PubMed, CrossRef
  31. Semenza GL. A compendium of proteins that interact with HIF-1α. Exp Cell Res. 2017;356(2):128-135. PubMed, PubMedCentral, CrossRef
  32. Sliusar MY, Minchenko DO, Khita OO, Tsymbal DO, Viletska YM, Luzina OY, Danilovskyi SV, Ratushna OO, Minchenko OH. Hypoxia controls the expression of genes responsible for serine synthesis in U87MG cells on ERN1-dependent manner. Endocr Regul. 2023;57(1):252-261. PubMed, CrossRef
  33. Papandreou I, Benej M, Denko NC. Unanticipated metabolic plasticity in response to chronic hypoxia. Cell Metab. 2023;35(3):381-383. PubMed, CrossRef
  34. Chan MC, Ilott NE, Schödel J, Sims D, Tumber A, Lippl K, Mole DR, Pugh CW, Ratcliffe PJ, Ponting CP, Schofield CJ. Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases. J Biol Chem. 2016;291(39):20661-20673. PubMed, PubMedCentral, CrossRef
  35. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92(12):5510-5514. PubMed, PubMedCentral, CrossRef
  36. Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;132(11):e159839. PubMed, PubMedCentral, CrossRef
  37. Yfantis A, Mylonis I, Chachami G, Nikolaidis M, Amoutzias GD, Paraskeva E, Simos G. Transcriptional Response to Hypoxia: The Role of HIF-1-Associated Co-Regulators. Cells. 2023;12(5):798. PubMed, PubMedCentral, CrossRef
  38. inchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest. 1994;71(3):374-379. PubMed
  39. Minchenko O, Opentanova I, Caro J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett. 2003;554(3):264-270. PubMed, CrossRef
  40. Minchenko OH, Tsuchihara K, Minchenko DO, Bikfalvi A, Esumi H. Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells. World J Gastroenterol. 2014;20(38):13705-13717. PubMed, PubMedCentral, CrossRef
  41. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5(5):343-354. PubMed, CrossRef
  42. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002;16(10):1151-1162. PubMed, CrossRef
  43. Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci. 2009;66(22):3539-3554. PubMed, PubMedCentral, CrossRef
  44. Pugh CW. Modulation of the Hypoxic Response. Adv Exp Med Biol. 2016;903:259-271. PubMed, CrossRef
  45. Aschner M, Skalny AV, Lu R, Santamaria A, Zhou JC, Ke T, Karganov MY, Tsatsakis A, Golokhvast KS, Bowman AB, Tinkov AA. The role of hypoxia-inducible factor 1 alpha (HIF-1α) modulation in heavy metal toxicity. Arch Toxicol. 2023;97(5):1299-1318. PubMed, CrossRef
  46. Engel AL, Lorenz NI, Klann K, Münch C, Depner C, Steinbach JP, Ronellenfitsch MW, Luger AL. Serine-dependent redox homeostasis regulates glioblastoma cell survival. Br J Cancer. 2020;122(9):1391-1398. PubMed, PubMedCentral, CrossRef
  47. Ye J, Huang X, Tian S, Wang J, Wang H, Feng H, Zhao X, Cao S, Xuan Y, Li X, Ma X, Huang Y, Zhang X. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma. Exp Cell Res. 2024;437(1):113977. PubMed, CrossRef
  48. Gao S, Ge A, Xu S, You Z, Ning S, Zhao Y, Pang D. PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer. J Exp Clin Cancer Res. 2017;36(1):179. PubMed, PubMedCentral, CrossRef
  49. Yang Z, Xu T, Xie T, Yang L, Wang G, Gao Y, Xi G, Zhang X. CDC42EP3 promotes glioma progression via regulation of CCND1. Cell Death Dis. 2022;13(4):290. PubMed, PubMedCentral, CrossRef
  50. Shen S, Liu R, Huang J, Sun Y, Tan Q, Luo Q, Liu R. MAT1A activation of glycolysis to promote NSCLC progression depends on stabilizing CCND1. Cell Death Dis. 2024;15(10):768. PubMed, PubMedCentral, CrossRef
  51. Wang D, Wang J, Yao F, Xie Z, Wu J, Chen H, Wu Q. miR-1247-3p regulation of CCND1 affects chemoresistance in colorectal cancer. PLoS One. 2024;19(12):e0309979. PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.